	US 11,912,766 B2
	Anti-Siglec-7 antibodies having reduced effector function
Christopher Bebbington, San Carlos, CA (US); Wouter Korver, San Carlos, CA (US); and Nenad Tomasevic, San Carlos, CA (US)
Assigned to Allakos, Inc., Redwood City, CA (US)
Appl. No. 16/961,197
Filed by Allakos, Inc., San Carlos, CA (US)
PCT Filed Jan. 11, 2019, PCT No. PCT/US2019/013316 § 371(c)(1), (2) Date Jul. 9, 2020, PCT Pub. No. WO2019/140273, PCT Pub. Date Jul. 18, 2019.
Claims priority of provisional application 62/616,317, filed on Jan. 11, 2018.
Prior Publication US 2021/0054072 A1, Feb. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2803 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01); C07K 2317/77 (2013.01)]

11 Claims

1. An anti-Siglec-7 antibody that binds to Siglec-7;

wherein the anti-Siglec-7 antibody comprises a variant Fc region that comprises at least one amino acid amino acid modification that reduces effector function or increases antibody stability compared to the corresponding native Fc region, and wherein the antibody comprises:

(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:55 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:69;

(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:57 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:69; or

(c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:59 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:78.